Correction: Comparison of HBV-specific T cell reactivity across the pregnant, postpartum and non-pregnant women with chronic HBV infection

Frontiers Media SA 3 pregnant women (pregnant group), 26 patients giving birth within six months (postpartum group), and 31 non-pregnant patients at childbearing age (non-pregnant group) using the in-houseELISpot assay to compare HBV-specific T cell reactivity across the three groups. That study concluded that pregnancy reduced HBV-specific T cell reactivity in the women with chronic HBV infection, but NUC treatment may have improved specific T-cell function.The present study commenced after July, 2023, enrolling new patients to further confirm our previous findings. Finally, 283 HBV-infected patients (129 pregnant patients, 58 postpartum patients giving birth within six months, and 96 non-pregnant patients) were tested using the inhouse ELISpot assay. This study was submitted to Frontiers in Immunology on July 9, 2024, and differs from our prior study in its conclusions: here, we found that while pregnancy can reduce HBV-specific T cell reactivity in women with chronic HBV infection, NUC treatment did not improve their HBV-specific T cell reactivity.Two independent cohorts (100 patients in the first study, and 283 patients in the present study)were enrolled in these studies. The original version of this article has been updated.